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Abstract
Background: In the United Kingdom (UK), there is an extensive market for the class 'A' drug
heroin and many heroin users spend time in prison. People addicted to heroin often require
prescribed medication when attempting to cease their drug use. The most commonly used
detoxification agents in UK prisons are currently buprenorphine and methadone, both are
recommended by national clinical guidelines. However, these agents have never been compared for
opiate detoxification in the prison estate and there is a general paucity of research evaluating the
most effective treatment for opiate detoxification in prisons. This study seeks to address this
paucity by evaluating the most routinely used interventions amongst drug users within UK prisons.
Methods/Design: This study uses randomised controlled trial methodology to compare the open
use of buprenorphine and methadone for opiate detoxification, given in the context of routine care,
within three UK prisons. Prisoners who are eligible and give informed consent will be entered into
the trial. The primary outcome will be abstinence status eight days after detoxification, as
determined by a urine test. Secondary outcomes will be recorded during the detoxification and
then at one, three and six months post-detoxification.
Trial registration: Current Controlled Trials ISRCTN58823759
Background
In the United Kingdom (U.K), there is an extensive market
for the sale of heroin, an illicit class 'A' drug. Precise fig-
ures of how many people use and are dependent on her-
oin are difficult to establish as there has never been a
national prevalence survey [1]. However, a 2004 survey
found that 67% of people receiving drug treatment (out of
a population of 125 545) identified heroin as their main
problem drug [2]. The link between crime and illicit drug
use, specifically heroin use, is well recognised. In 2002,
63% of injecting drug users (IDUs) in contact with spe-
cialist drugs services in England and Wales reported hav-
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ing ever been in prison or a young offenders' institution
[3]. Because of the drug's highly addictive properties,
those addicted to illicit opiates such as heroin require
medical help in reducing and stopping their use.
Previously, neither the evidence base [1] nor the UK
national guidelines on the clinical management of drug
misuse [4] stipulated a 'drug of choice' for opiate detoxifi-
cation in the prison setting. In the absence of an estab-
lished evidence base, a wide variety of agents have
therefore been used, they include methadone, dihydroco-
deine, buprenorphine, lofexidine and clonidine. Cur-
rently, methadone and buprenorphine are recommended
by national clinical guidelines [5]. Prior to the mid 2000s,
the most commonly used drug for opiate detoxification
had been dihydrocodeine. Anecdotally, dihydrocodeine
was used because of a reluctance to prescribe methadone
following a small number of methadone related deaths in
prisons. Dihydrocodeine is attractive to clinicians as it has
a shorter half-life than methadone, and seems equally
acceptable to users. There was a move away from prescrib-
ing dihydrocodeine because of its potential for diversion
by prisoners into the prison shadow economy, buprenor-
phine has been increasingly prescribed. Buprenorphine –
in the form of sub-lingual tablets – has the potential
advantage of having a good safety profile, a higher rate of
adherence and lower withdrawal severity when compared
to methadone, lofexidine or clonidine [6-9]. Its introduc-
tion into the prison estate was in line with increasing pre-
scribing in the community [10]. An evidence base exists in
the community for the effectiveness of methadone in
achieving detoxification [4]. In 2004, policy initiatives
recommended increasing the provision of methadone
programmes within the prison setting [11]. Conse-
quently, methadone was re-introduced into the prison
estate in accordance with current best practice guidelines
for prescription and administration.
Despite the changes highlighted above regarding recom-
mendations for first-line agents, few clinical trials con-
ducted in the UK prison setting have evaluated
medication for opiate detoxification. Whilst one study
evaluated the withdrawal severity of methadone and
lofexidine [12], the rates of completion were not sufficient
to detect a statistically significant difference between the
two medications. In 2004, the Leeds Evaluation of Effi-
cacy of Detoxification Study (LEEDS) team conducted the
first randomised controlled trial (RCT) comparing
buprenorphine and dihydrocodeine for opiate detoxifica-
tion in the community [13,14]. The research team then
compared these two agents in a pilot trial in HMP (Her
Majesty's Prison) Leeds [15], and recently submitted the
results for publication. The LEEDS trial has since
expanded to compare the open use of buprenorphine to
methadone across healthcare in several prisons.
Methods
Design
LEEDS is a pragmatic open label randomised controlled
trial.
Randomisation is by random block size, which CA
administers centrally. He prepares opaque consecutively
numbered envelopes. If a prisoner is both eligible and
agreeable, the next envelope is opened and the interven-
tion allocated. Randomisation controls for confounding
variables (e.g. doctor-participant relationships, drugs
worker-participant).
Setting and Recruitment
The study is taking place in prison healthcare at HMP
Leeds and HMP New Hall in West Yorkshire and HMP
Durham in County Durham, England. All prisons are cat-
egory B. (this refers to a prison which is high but not max-
imum security). HMP Leeds is a local prison, it accepts
only adult male prisoners aged 21 and over from West
Yorkshire. HMP New Hall, based in a rural location, is a
local women's prison for adult females. HMP Durham
accepts male prisoners from the North East of England.
NB, RH and BR recruit participants from the medical
reception area on first arrival into HMP Leeds, where pris-
oners are routinely offered a detoxification regime.
Recruitment began in HMP Leeds in January 2006, HMP
Durham in February 2007 and in HMP New Hall in Janu-
ary 2008. Data collection is ongoing.
Sample size
In the situation of helping people detoxify from heroin,
even a small advantage for an intervention could repre-
sent a worthwhile benefit. Therefore LEEDS has been
planned to detect even a 15% difference in the proportion
of opiate-free patients within the detoxification period i.e.
percentage already abstinence 35% in one group and 50%
in the other group. LEEDS expects to recruit 340 partici-
pants. A sample size of 340 people would yield at least an
80% chance (1 - β error or power) of detecting an absolute
difference of 15% between the proportion of opiate-free
patients in each group, at a two sided 5% level of signifi-
cance (α error).
Eligibility
Inclusion criteria
1. Male or female
2. 18 – 65 years old
3. Using illicit opiates as confirmed by a urine test
taken at first assessment
4. Expressing a wish to detoxify through the standard
monitored process and remain abstinent from opiatesTrials 2009, 10:53 http://www.trialsjournal.com/content/10/1/53
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5. Willing to give informed consent after receiving the
participant information booklet
6. Remaining in custody for at least 28 days
Exclusion criteria
1. Contraindications to methadone or buprenorphine
2. Co-existing acute medical conditions requiring
emergency admission for hospital care thus preclud-
ing detoxification in the prison setting
3. Currently undergoing detoxification from other
addictive drugs whereby concurrent detoxification
from opiates would not be clinically indicated
4. Previously been randomised into this trial
Interventions
The treatment option will be concealed from both the par-
ticipant and clinician/drugs worker at time of assessment.
Both parties will remain blind to the selected treatment
option until the envelope is opened.
1. Methadone, given openly, in the context of the
standard prison doctor and drugs worker support.
2. Buprenorphine, given openly, in the context of the
standard prison doctor and drugs worker support.
The reducing regimen of both methadone and buprenor-
phine (over less than 20 days) will be at the discretion of
the prescribing doctor. However, the dose should not
exceed this standard regime (Table 1).
Consent
Consent for the participant to enter the trial is gained at
first presentation to the prison doctor or drugs worker
after confirmation of eligibility criteria. Written consent
will be obtained after the participant has made an
informed decision. Information will be provided to the
participant using an information leaflet documenting the
aims, objectives and necessity of the study. The study has
been approved by the research ethics committee (MREC
Northern and Yorkshire).
Outcomes
Primary outcome
Abstinence from illicit opiates at eight days post detox as
indicated by urine test. A person who does not finish the
course of detoxification or refuses to give urine will be
considered not abstinent. If participants are released
before the date of the urine test then the primary outcome
will be based on self report in the community. If self
report date is unobtainable then they will be noted as
"loss to follow up".
Secondary outcomes
During the period of detoxification
Adverse events
Clinicians will record any details of adverse events in the
usual way by making an entry in the participants' records.
The researchers based at the prisons inform LS immedi-
ately of any adverse events clearly resulting in clinically
significant distress to study participants or of major con-
cern to clinicians. Any serious or adverse events are then
reported to regulatory authorities
Leaving the study early
Perceived reasons for withdrawal are recorded.
Inappropriate use of prescribed medication
Examples of this include storing, trading, swapping or
selling of prescribed medication.
Overdose, self harm or suicide attempt
Service related outcomes
In-patient stays in prison healthcare will be recorded as
will visits to a doctor, nurse or drugs worker
At one-month, three-month and six-month post detoxifi-
cation
Table 1: Detoxification schedules
Day Buprenorphine
(mg)
Methadone
(1 mg/1 ml mixture)
18 3 0
28 3 0
38 3 0
48 3 0
58 3 0
66 2 5
76 2 5
84 2 2
94 2 2
10 4 20
11 3.6 20
12 3.6 18
13 3.2 16
14 2.8 14
15 2.4 12
16 2.0 10
17 1.6 8
18 1.2 6
19 0.8 4
20 0.4 2Trials 2009, 10:53 http://www.trialsjournal.com/content/10/1/53
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Abstinence status
Abstinence ascertained via urine test if the participant is
still in HMP Leeds, Durham or New Hall, or has been
transferred to another prison. If the participant has been
released into the community then local community drugs
service records are accessed.
All other outcomes as detailed above if the participant is
still in the prison environment in which they were ran-
domised.
The project team recognise the difficulty in tracking peo-
ple with drug problems who have subsequently been
released from prison across this period, particularly
through the experience of conducting our pilot trial [15].
Data collection
In HMP Leeds, NB, RH and BR collect baseline demo-
graphic data at randomisation. RH and NB collect the pri-
mary outcome and data at one, three months and six
months after randomisation. Nursing staff and drugs
workers collect data in the other centres. LS collates all
data. There will be minimal additional contact with the
participants. LEEDS is designed to avoid complicating the
care provided to this group.
Analysis
LS enters all data into an Excel spreadsheet. The analysis
will be undertaken using Epi-Info software. The analysis
of the primary outcomes will be of a 2 × 2 table (see Table
2). Dummy tables have been constructed for all secondary
outcomes. These tables are designed to be rigid templates
for the final write-up of the project, and to protect the
researchers from bias, once the data are disclosed. Analy-
sis will use relative risk tests for categorical data and
unpaired t-tests for continuous data.
Discussion
As with our pilot trial in HMP Leeds [15], the information
which the LEEDS project team aim to gain from this cur-
rent trial is twofold. Firstly, once data collection is com-
plete, we hope to show either a statistically significant
difference between the efficacy of the two detoxification
agents or alternatively, that no statistically significant dif-
ference exists (shown by p = > 0.05). We expect that the
results will influence national prison healthcare policy
and prescribing guidelines if the trial demonstrates one
detoxification agent is significantly more efficacious than
another.
Information about the methodological practicalities of
conducting a multi centre, randomised controlled trial in
the prison setting will be valuable. The research team have
previously described the practicalities of conducting a
detoxification RCT in primary care [13,14]. To our knowl-
edge, however, only one British prison RCT comparing
detoxification agents exists [12] aside from our prison
pilot trial [15]. Therefore, conducting this current trial will
provide new knowledge about the feasibility, practicality
and day to day groundwork and management involved in
running a trial in multiple prisons. This information may
be important for future research teams. If successful, the
trial will demonstrate the feasibility of multi centre trials
within this environment.
Guidelines for substance misuse treatment in prison are
not grounded on an established evidence base as there are
very few trials conducted in this setting. Consequently, the
project team envisage that this trial will provide valuable
data about the efficacy of two routinely used detoxifica-
tion agents which have rarely been studied within the
prison environment.
Approvals process
The extensive process of obtaining all necessary approvals
for this trial and the issues surrounding this have been
fully discussed in Sheard et al (2006) [16]. Research Gov-
ernance approval was granted by Bradford South and
West Primary Care Trust (PCT) on 2nd December 2004.
Research Ethics approval was granted from Multi Centre
Research Ethics Committee (MREC) Northern and York-
shire on 5th July 2005.
The approval of the sponsor was gained on 28th June
2005. A Clinical Trials Authority Certificate was issued
from the Medicines and Healthcare Products Regulatory
Authority on 28th  September 2005. The International
Standard Randomised Controlled Trials number was
granted on 15th September 2005 (but backdated to 16
August 2005). Research governance for HMP Durham as
Table 2: Dummy table for abstinence from illicit heroin at final prescription as indicated by urine test
Abstinence successful Abstinence not successful Totals
Buprenorphine A C A+C
Methadone B D B+D
Totals A+B C+D A+B+C+DPublish with BioMed Central    and   every 
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an additional centre was granted by County Durham Pri-
mary Care Trust on 23rd October 2006.
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